Sanctuary Advisors LLC Makes New $755,000 Investment in argenx SE (NASDAQ:ARGX)

Sanctuary Advisors LLC bought a new position in shares of argenx SE (NASDAQ:ARGX) in the second quarter, Holdings Channel reports. The firm bought 1,756 shares of the company’s stock, valued at approximately $755,000.

A number of other large investors have also recently added to or reduced their stakes in ARGX. Clearbridge Investments LLC boosted its position in shares of argenx by 3.6% in the second quarter. Clearbridge Investments LLC now owns 617,466 shares of the company’s stock valued at $265,535,000 after acquiring an additional 21,189 shares during the period. Perceptive Advisors LLC bought a new stake in shares of argenx in the second quarter valued at approximately $6,709,000. Creative Planning boosted its position in shares of argenx by 15.5% in the second quarter. Creative Planning now owns 3,528 shares of the company’s stock valued at $1,517,000 after acquiring an additional 474 shares during the period. Driehaus Capital Management LLC boosted its position in shares of argenx by 69.9% in the second quarter. Driehaus Capital Management LLC now owns 28,309 shares of the company’s stock valued at $12,174,000 after acquiring an additional 11,642 shares during the period. Finally, Mackenzie Financial Corp boosted its position in shares of argenx by 8.4% in the second quarter. Mackenzie Financial Corp now owns 2,265 shares of the company’s stock valued at $974,000 after acquiring an additional 176 shares during the period. Institutional investors own 60.32% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ARGX shares. Robert W. Baird increased their price objective on argenx from $490.00 to $515.00 and gave the company an “outperform” rating in a research report on Monday, July 29th. JPMorgan Chase & Co. raised their target price on argenx from $500.00 to $640.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. Deutsche Bank Aktiengesellschaft cut argenx from a “buy” rating to a “hold” rating in a research report on Friday, October 4th. William Blair reaffirmed a “market perform” rating on shares of argenx in a research report on Monday, June 17th. Finally, Wells Fargo & Company raised their target price on argenx from $543.00 to $547.00 and gave the stock an “overweight” rating in a research report on Friday, July 26th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $548.00.

argenx Stock Performance

Shares of NASDAQ:ARGX opened at $536.70 on Monday. argenx SE has a twelve month low of $327.73 and a twelve month high of $554.74. The firm has a market cap of $31.90 billion, a PE ratio of -94.82 and a beta of 0.63. The business has a fifty day moving average of $527.60 and a 200-day moving average of $448.91.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, July 25th. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $1.34. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. The company had revenue of $489.43 million during the quarter, compared to analyst estimates of $436.66 million. During the same period last year, the company posted ($1.69) earnings per share. On average, analysts anticipate that argenx SE will post -0.37 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.